GPE – Page 22 – Talk Bio

Actionable Insights Powered by AI

FDA Reconsiders Removal of Eli Lilly’s Tirzepatide from Shortage List, Boosting Compounding Pharmacies

11 months ago talkbio0Tagged Compound, Diabetes Mellitus, Non-Insulin-Dependent, Eli, Eli Lilly, Glucagon-Like Peptide 1, Pharmacy facility, shortage, tirzepatide, United States Food and Drug Administration

FDA, Eli Lilly, Tirzepatide, GLP-1 drug, Shortage list, Compounding pharmacies, Weight loss medication, Type 2 diabetes treatment

Eli Lilly Commits £279 Million to UK Life Sciences Sector in Groundbreaking Partnership

11 months ago talkbio0Tagged Biological Science Disciplines, Eli, Eli Lilly, Gateway Labs, Government, Investments, Obesity, Partnership, UK

Eli Lilly, UK life sciences, £279 million investment, Lilly Gateway Labs, obesity treatment, UK government partnership

Catalent Sells New Jersey Facility and HQ to Ardena, Expanding Belgian CDMO’s US Footprint

11 months ago talkbio0Tagged Ardena, Catalent, CDMO, expansion, HQ, Jersey manufacturing, pharmaceutical manufacturing, Plants

Catalent, Ardena, New Jersey manufacturing plant, HQ sale, CDMO expansion, pharmaceutical manufacturing

FDA Approves Roche’s Itovebi, a PI3K Inhibitor for Advanced Breast Cancer Treatment

11 months ago talkbio0Tagged Approved, HER2-negative, Hormones, Itovebi, Malignant neoplasm of breast, PI3 K inhibitor, PIK3CA Gene Mutation, receptor-positive, Roche (company), United States Food and Drug Administration

Roche, Itovebi, PI3K inhibitor, breast cancer, FDA approval, PIK3CA mutation, hormone receptor-positive, HER2-negative

Eli Lilly Rekindles Partnership with KeyBioscience to Bolster Obesity Drug Pipeline

11 months ago talkbio0Tagged Eli, Eli Lilly, KeyBioscience, Obesity, partnerships, Weight Loss

Eli Lilly, obesity drugs, KeyBioscience, partnerships, weight loss treatments

Glooko Secures $100 Million Funding to Enhance Diabetes Management Platform Under New Leadership

11 months ago talkbio0Tagged Administration occupational activities, Diabetes, Glooko, Healthcare technology, Leadership

Glooko, diabetes management, healthcare technology, funding, new leadership

Astellas Reduces Universal Cells Workforce in Seattle, Relocates 12 Positions to Japan

11 months ago talkbio0Tagged Astellas, Cell Therapy, Japan, Seattle, Universal Cells

Astellas, Universal Cells, layoffs, Seattle, Japan, cell therapy, biotech

Kaleo Announces 58 Layoffs Despite Recent Expansion Plans for EpiPen Rival Auvi-Q

11 months ago talkbio0Tagged Auvi-Q, Drug Industry, EpiPen competitor, Kaleo layoffs, Richmond-based company

Kaleo layoffs, Auvi-Q, EpiPen competitor, pharmaceutical industry, job cuts, Richmond-based company

BIOSECURE Act: A Potential Game-Changer for Biopharma – Industry Implications and Future Directions

11 months ago talkbio0Tagged Biopharma Industry, BIOSECURE, Biotechnology, regulatory, Relations, Supply chain diversification, U.S., U.S.-China

BIOSECURE Act, Biopharma industry, US-China relations, Biotechnology collaborations, Supply chain diversification, Regulatory compliance

BIOSECURE Act: Navigating Industry Implications and Future Directions

11 months ago talkbio0Tagged BIOSECURE, Biotechnology, capabilities, CDMOs, Chinese Language, Contract agreement, development aspects, Industry, Manufacture, manufacturing organizations, pharmaceutical imports, Pharmaceutical supply chain resilience, Supply chain disruptions, United States

BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience